AU2003235789A8 - Novel apoptosis-inducing dna sequences - Google Patents

Novel apoptosis-inducing dna sequences

Info

Publication number
AU2003235789A8
AU2003235789A8 AU2003235789A AU2003235789A AU2003235789A8 AU 2003235789 A8 AU2003235789 A8 AU 2003235789A8 AU 2003235789 A AU2003235789 A AU 2003235789A AU 2003235789 A AU2003235789 A AU 2003235789A AU 2003235789 A8 AU2003235789 A8 AU 2003235789A8
Authority
AU
Australia
Prior art keywords
dna sequences
inducing dna
novel apoptosis
apoptosis
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU2003235789A
Other versions
AU2003235789A1 (en
Inventor
Rolf Schafer
Kerstin Konig-Hoffman
Michael Kazinski
Bjorn Kesper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xantos Biomedicine AG
Original Assignee
Xantos Biomedicine AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xantos Biomedicine AG filed Critical Xantos Biomedicine AG
Publication of AU2003235789A1 publication Critical patent/AU2003235789A1/en
Publication of AU2003235789A8 publication Critical patent/AU2003235789A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
AU2003235789A 2002-01-11 2003-01-13 Novel apoptosis-inducing dna sequences Abandoned AU2003235789A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10200856 2002-01-11
DE10200856.6 2002-01-11
PCT/EP2003/000270 WO2003058021A2 (en) 2002-01-11 2003-01-13 Novel apoptosis-inducing dna sequences

Publications (2)

Publication Number Publication Date
AU2003235789A1 AU2003235789A1 (en) 2003-07-24
AU2003235789A8 true AU2003235789A8 (en) 2003-07-24

Family

ID=7711922

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003235789A Abandoned AU2003235789A1 (en) 2002-01-11 2003-01-13 Novel apoptosis-inducing dna sequences

Country Status (2)

Country Link
AU (1) AU2003235789A1 (en)
WO (1) WO2003058021A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004263303A1 (en) * 2003-08-07 2005-02-17 F. Hoffmann-La Roche Ag RA antigenic peptides
DE10345010A1 (en) * 2003-09-22 2005-04-28 Eike Staub Use of the receptor Nifie14, or nucleic acid encoding it, for detecting cancer, or the risk of developing it, also use of Nifie 14 binding agents for diagnosis and treatment of cancer
GB0328048D0 (en) * 2003-12-04 2004-01-07 Univ Sheffield Gene screen
GB0516058D0 (en) * 2005-08-04 2005-09-14 Oxford Genome Sciences Uk Ltd New protein isoforms and uses thereof
EP1837404A1 (en) * 2006-03-24 2007-09-26 Universität Zu Köln Mutant lysosomal type 5 P-type ATPase ATP13A2 and its use for diagnosis and therapy of neurodegenerative disorders
US20070237713A1 (en) 2006-04-04 2007-10-11 Fan Rong A PCan065 Antibody Compositions and Methods of Use
US9518107B2 (en) 2010-08-31 2016-12-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Pharmaceutical compositions containing polypeptides derived from α-1 antitrypsin and methods of use thereof
WO2012029061A2 (en) 2010-08-31 2012-03-08 Uri Wormser POLYPEPTIDES DERIVED FROM α-1 ANTITRYPSIN AND METHODS OF USE THEREOF
CN103030688B (en) * 2011-09-30 2014-09-17 北京大学 Short chain polypeptide for inhibiting cancer cell growth as well as encoding gene and application of short chain polypeptide
US9265789B2 (en) * 2013-03-12 2016-02-23 The Medical College Of Wisconsin, Inc. Targeting CLPTM1L by RNA interference for treatment and prevention of cancer
KR101540319B1 (en) * 2013-10-01 2015-07-30 한국생명공학연구원 Pharmacological composition containing a cyb5R3 protein or a polynucleotide encoding cyb5R3 for the prevention and treatment of cancer

Also Published As

Publication number Publication date
WO2003058021A2 (en) 2003-07-17
AU2003235789A1 (en) 2003-07-24
WO2003058021A3 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
HK1211600A1 (en) Anti-vegf antibodies -vegf
IL172429A0 (en) Novel aminobenzophenone compounds
AU2003286588A8 (en) Methods for synthesizing complementary dna
AU2003235789A8 (en) Novel apoptosis-inducing dna sequences
GB0323090D0 (en) Novel process
GB0323043D0 (en) Biochip
GB0611515D0 (en) Novel oxy-nitriles
HK1098484A1 (en) Motoneuronotrophic factor gene sequences
AU2003223331A8 (en) Constructing very long dna sequences from synthetic dna molecules
GB0126164D0 (en) Sequences
AU2001276406A1 (en) Apoptosis-inducing dna sequences
GB0111194D0 (en) Sequences
GB0218089D0 (en) Target DNA
GB0308406D0 (en) Polypeptide sequences
GB0308404D0 (en) Polypeptide sequences
AUPR495201A0 (en) Novel dna sequences
ZA200708564B (en) Glycopegylated erythropoletin
GB0214945D0 (en) Sequences
GB0215980D0 (en) Sequences
EP1518929A4 (en) Novel genes
GB0327195D0 (en) Novel use
GB0115225D0 (en) Nucleotide sequences
GB0326598D0 (en) Gene
GB0313773D0 (en) Gene
GB0301622D0 (en) Parallel sequencing technology-d

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase